Table 2. Minimum Inhibitory Concentrationsa (MIC) of 15 Antiretorovirals and 9 Combinatorial Treatment against E. coli, Bacteroides spp., Prevotella spp., and E. faecalis.
| compound | abbreviation | MIC (mg/L) |
|||
|---|---|---|---|---|---|
| E. coli | Bacteroides spp. | Prevotella spp. | E. faecalis | ||
| non-nucleoside reverse transcriptase inhibitors | |||||
| Efavirenz | EFV | >256 | 32–128 | 32 | 16–32 |
| Nevirapine | NVP | >256 | >256 | >256 | >256 |
| Rilpivirine | RPV | >128 | >128 | >128 | >128 |
| nucleoside reverse-transcriptase inhibitors | |||||
| Abacavir | ABC | >256 | >256 | >256 | >256 |
| Emtricitabine | FTC | >128 | >128 | >128 | >128 |
| Lamivudine | 3TC | >128 | >128 | >128 | >128 |
| Stavudine | d4T | >256 | >256 | >256 | >256 |
| Zidovudine | ZDV | 0.5–1 | 4–8 | 4 | >128 |
| Tenofovir | TFV | >256 | >256 | >256 | >256 |
| Tenofovir disoproxil fumarate | TDF | >128 | >128 | >128 | >128 |
| Tenofovir Alafenamide | TAF | >128 | >128 | >128 | >128 |
| protease inhibitors | |||||
| Atazanavir | ATV | >256 | >256 | >256 | >256 |
| Darunavir | DRV | >512 | >512 | >512 | >512 |
| Lopinavir | LPV | >128 | >128 | >128 | >128 |
| Ritonavir | RTV | >128 | >128 | >128 | >128 |
| combinations | |||||
| EFV/FTC/TDF | >240:100:120 | 30:12:15 | 15:6:7.5 | 30:12:15 | |
| 3TC/ZDV/EFV | 30:25:60 | 15:12:30 | 15:12:30 | 30:25:60 | |
| EFV/ABC/3TC | >240:240:120 | 30:30:15 | 30:30:15 | 30:30:15 | |
| TDF/FTC/RPV | >120:100:80 | >120:100:80 | >120:100:80 | >120:100:80 | |
| TDF/FTC/NVP | >120:100:160 | >120:100:160 | >120:100:160 | >120:100:160 | |
| 3TC/ABC/DRV | >120:240:320 | >120:240:320 | >120:240:320 | >120:240:320 | |
| 3TC/ABC/LPV | >120:240:120 | >120:240:120 | >120:240:120 | >120:240:120 | |
| TDF/FTC/LPV | >120:100:120 | >120:100:120 | >120:100:120 | >120:100:120 | |
| TDF/FTC/DRV | >120:100:320 | >120:100:320 | >120:100:320 | >120:100:320 | |
a
The values are from biological triplicates.